Tesamorelin

What Is Tesamorelin?

Tesamorelin is a synthetic GHRH analog (trans-3-hexenoic acid-modified) with FDA approval for HIV-associated lipodystrophy. Phase 3 data demonstrated significant visceral adipose tissue (VAT) reduction and improved metabolic markers. As a GHRH analog, it stimulates endogenous GH release from the pituitary rather than providing exogenous GH directly.

Research Context

• Visceral adipose tissue reduction via GHRH-driven GH axis stimulation
• Lipodystrophy and metabolic syndrome models (FDA approval basis)
• GH and IGF-1 elevation through endogenous pituitary stimulation
• Cardiovascular risk factor modulation: triglycerides, HDL, inflammatory markers
• Comparison with other GHRH analogs (CJC-1295) for clinical translation research